| pubmed-article:17634548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17634548 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:17634548 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17634548 | lifeskim:mentions | umls-concept:C0345967 | lld:lifeskim |
| pubmed-article:17634548 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:17634548 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:17634548 | pubmed:dateCreated | 2007-7-19 | lld:pubmed |
| pubmed-article:17634548 | pubmed:abstractText | CD26 is a 110-kDa cell surface antigen with a role in tumor development. In this report, we show that CD26 is highly expressed on the cell surface of malignant mesothelioma and that a newly developed humanized anti-CD26 monoclonal antibody (mAb) has an inhibitory effect on malignant mesothelioma cells in both in vitro and in vivo experiments. | lld:pubmed |
| pubmed-article:17634548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17634548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17634548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17634548 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:17634548 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:YamochiTadano... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:MorimotoChika... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:TanakaHirotos... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:YamadaTaketoT | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:KatsuokaYojiY | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:HosonoOsamuO | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:OhnumaKeiK | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:DangNam HNH | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:KinaShinichir... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:TakahashiNozo... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:InamotoSakiko... | lld:pubmed |
| pubmed-article:17634548 | pubmed:author | pubmed-author:InamotoTeruoT | lld:pubmed |
| pubmed-article:17634548 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17634548 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17634548 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:17634548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17634548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17634548 | pubmed:pagination | 4191-200 | lld:pubmed |
| pubmed-article:17634548 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:meshHeading | pubmed-meshheading:17634548... | lld:pubmed |
| pubmed-article:17634548 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17634548 | pubmed:articleTitle | Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. | lld:pubmed |
| pubmed-article:17634548 | pubmed:affiliation | Division of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Japan. | lld:pubmed |
| pubmed-article:17634548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17634548 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17634548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17634548 | lld:pubmed |
